No data to show
OTCM
EVLO
Market cap9kUSD
Jul 09, Last price
0.00USD
1D
0.00%
1Q
0.00%
IPO
-100.00%
Name
Evelo Biosciences Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
241.55%
Rev. gr., 5y
%
Revenues
0k
Net income
-115m
L-6.26%
CFO
-101m
L+4.66%
Profile
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | 108,466 | ||||||
Unusual Expense (Income) | |||||||
NOPBT | (108,466) | ||||||
NOPBT Margin | |||||||
Operating Taxes | 930 | ||||||
Tax Rate | |||||||
NOPAT | (109,396) | ||||||
Net income | (114,527) -6.26% | ||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 84,544 | ||||||
BB yield | -60.24% | ||||||
| Debt | |||||||
Debt current | 2,259 | ||||||
Long-term debt | 56,403 | ||||||
Deferred revenue | 7,500 | ||||||
Other long-term liabilities | 659 | ||||||
Net debt | 10,722 | ||||||
| Cash flow | |||||||
Cash from operating activities | (101,235) | ||||||
CAPEX | (622) | ||||||
Cash from investing activities | (622) | ||||||
Cash from financing activities | 81,655 | ||||||
FCF | (105,574) | ||||||
| Balance | |||||||
Cash | 47,940 | ||||||
Long term investments | |||||||
Excess cash | 47,940 | ||||||
Stockholders' equity | (529,111) | ||||||
Invested Capital | 583,416 | ||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 4,358 | ||||||
Price | 32.20 -73.48% | ||||||
Market cap | 140,342 -56.30% | ||||||
EV | 151,064 | ||||||
EBITDA | (106,406) | ||||||
EV/EBITDA | |||||||
Interest | 4,672 | ||||||
Interest/NOPBT | |||||||